Sunday 24 November 2024

The Pharma Letter Podcast — Episode 5 — Innovation in preleukemia

Pharmaceutical
Simon Wentworth
1 October 2021
episode5-thepharmaletterpodcast

More on this story...

Biotechnology
Syros acquisition and stock sale line up shot at aggressive leukemia
7 December 2020
Biotechnology
The Pharma Letter Podcast — Episode 4 — The state of biotech investing
1 September 2021
Pharmaceutical
The Pharma Letter Podcast — Episode 3 — Psychedelics in medicine
18 August 2021
Biotechnology
FDA puts partial hold on Foghorn's Phase I study of FHD-286
20 May 2022


Companies featured in this story

More ones to watch >


Today's issue

Otsuka gains global licensing rights from Ionis to ulefnersen
Pharmaceutical
Otsuka gains global licensing rights from Ionis to ulefnersen
23 November 2024
Biotechnology
Anti-CD20 MAb Rituxan approved for ITP in Japan
23 November 2024
Biotechnology
J&J powers on with Tremfya with UC SC filing
22 November 2024
Biotechnology
Takeda launches Fruzaqla in Japan
22 November 2024
Biotechnology
CStone out-licenses sugemalimab rights in MENA region
22 November 2024
Biotechnology
China's regulator to review Akeso's checkpoint blocker
22 November 2024
Biotechnology
Paragon Therapeutics appoints first chief executive
22 November 2024

Company Spotlight

A Dutch clinical-stage company focused on the research and development of transformative therapies for cardio-metabolic diseases.




More Features in Pharmaceutical

Otsuka gains global licensing rights from Ionis to ulefnersen
23 November 2024
Pfizer to help commercialize Xacduro in China
22 November 2024
Amid RFK Jr vaccine worries, FDA’s Peter Marks remains calm
22 November 2024
Eisai announces launch of Rozebalamin and Tasfygo
21 November 2024


Copyright © The Pharma Letter 2024   |   Headless Content Management with Blaze